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Objective: Cesarean scar pregnancy (CSP) is a rare potentially life-threatening form of ectopic gestation.
However, optimal management has not yet been established. Furthermore, there are limited reports on
the diagnostic value of three-dimensional computed tomographic angiography (3D-CTA) for the con-
servative management of this disorder.
Case report: A 33-year-old woman (gravida 3, para 2), with two previous deliveries by low segmental
transverse cesarean section, was referred after 5 weeks of amenorrhea. Her serum beta-human chorionic
gonadotropin (b-hCG) value was 2921 mIU/mL. Cesarean scar pregnancy was diagnosed by ultraso-
nography and magnetic resonance imaging. On 3D-CTA, a prominent uteroplacental neovascularized
mass was identiﬁed. It was supplied by the left uterine artery and a thick draining left ovarian vein. After
three cycles of systemic methotrexate (MTX) administration, the serum b-hCG value decreased to
142 mIU/mL. However, the gestational sac enlarged and peritrophoblastic blood ﬂow persisted. In
contrast to the ultrasonographic ﬁndings, marked reduction of uteroplacental neovascularization at the
CSP site with regression of the draining ovarian vein was evident on 3D-CTA. The gestational products
were thereafter successfully resected by hysteroscopic surgery without hemorrhagic complications.
Fifty-seven days after the initial MTX administration, serum b-hCG reached a normal level.
Conclusion: This case emphasizes that, when selecting the method of intervention, 3D-CTA is potentially
useful for evaluating uteroplacental neovascularization in a hemodynamically stable CSP.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Cesarean scar pregnancy (CSP) is a rare but extremely dangerous
form of ectopic gestation in which the embryo is embedded in the
myometrial defect of the lower uterine segment at the site of a
previous cesarean section scar [1]. The optimal management of this
potentially life-threatening disorder has not yet been established,
and a variety of therapeutic procedures are still determined indi-
vidually without clear management consensus [2].
Our previous report showed that three-dimensional computed
tomographic angiography (3D-CTA) is a feasible diagnostic mo-
dality to evaluate neovascularization in CSP with signiﬁcant hem-
orrhage prior to transcatheter arterial chemoembolization [3]. Inand Gynecology, Gifu Prefec-
507-8522, Japan.
da).
bstetrics & Gynecology. Publishedthe present case report, successful fertility-sparing management of
a hemodynamically stable CSP by using the systemic administra-
tion of methotrexate (MTX), followed by hysteroscopic resection, is
described with the assessment of the interval change of uteropla-
cental neovascularization at the CSP site by 3D-CTA.
Case report
A 33-year-old woman (gravida 3, para 2), who had two previous
deliveries by low segmental transverse cesarean section, was
referred with a suspected CSP after 5 weeks of amenorrhea. Phys-
ical examination did not detect any remarkable symptoms and did
not detect uterine bleeding. The serum beta-human chorionic
gonadotropin (b-hCG) value was 2921 mIU/mL (Fig. 1). Hemody-
namically stable CSP was diagnosed by initial color Doppler ultra-
sonography when the gestational sac, which measured 7.6 mm
with peritrophoblastic blood ﬂow (Fig. 2A, arrow), was identiﬁed in
the previous cesarean scar of a lower uterine segment. The ectopicby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Changes in serum beta-human chorionic gonadotropin levels related to the
treatment of a hemodynamically stable cesarean scar pregnancy. The patient under-
went systemic administration of methotrexate (20 mg/body for 5 consecutive days) for
three cycles, followed by successful hysteroscopic removal of the retained gestational
products. b-hCG ¼ beta-human chorionic gonadotropin; MTX ¼ methotrexate.
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magnetic resonance imaging (MRI) (Fig. 2B, arrow). On the coro-
nal reconstructed multiplanar image of 3D-CTA (Fig. 2C), a promi-
nent neovascularized mass with an arteriovenous shunt-like
structure (Fig. 2C, arrow) was identiﬁed in the left lateral lower
uterine segment. It was supplied from the left uterine artery with a
thick draining left ovarian vein (Fig. 2C, arrowhead).
Because of the patient's strong wish to preserve fertility, she
underwent the systemic administration of MTX (20 mg/body for 5
consecutive days) beginning the day after the initial examination.
Seven days after the initial cycle of MTX, a temporary rise in the
serum b-hCG value to 6497 mIU/mL was noted. Ten days after the
MTX injection, a moderate hemorrhage occurred. The fetal pole
appeared, although fetal cardiac activity was not detected (Fig. 3A,Fig. 2. Diagnostic ﬁndings of the hemodynamically stable cesarean scar pregnancy on initial
(arrow) with the peritrophoblastic blood ﬂow localized in the anterior uterine wall at the pre
gestational sac (arrow) localized in the anterior uterine wall at the previous cesarean sc
tomographic angiography shows a prominent neovascularized mass with an arteriovenous
left ovarian vein (arrowhead) in the left lateral lower uterine segment.arrowhead) and peritrophoblastic blood ﬂow persisted (Fig. 3A,
arrow). Uterine bleeding was conservatively managed by vaginal
gauze packing. It ceased spontaneously. Additional systemic MTX
was then administered twice when a delayed decline in the serum
b-hCG value was noted (Fig. 1).
Forty-one days after the initial MTX administration, the serum
b-hCG value decreased to 142 mIU/mL. However, the size of the
gestational sac increased to 23.2 mm and peritrophoblastic blood
ﬂow persisted (Fig. 3B, arrow). Because liver damage (aspartate
aminotransferase, 67 IU/L; alanine transaminase, 126 IU/L) was
noteddpresumably because of the side effects of MTXdit was
concluded that further medical management would be difﬁcult
and surgical removal (e.g., hysteroscopic resection) should be
considered.
To determine the needs of preventive uterine arterial emboli-
zation prior to hysteroscopic resection, the uteroplacental neo-
vascularization was evaluated again by 3D-CTA. In contrast to the
ﬁndings by color Doppler ultrasonography, marked reduction of
neovascularization (Fig. 3C, arrow) at the CSP sitewith regression of
the draining ovarian vein was evident (Fig. 3C, arrowhead). On the
basis of this ﬁnding, 44 days after the initial MTX injection, hys-
teroscopic surgery was performed without preventive arterial
embolization [4]. The retained products of conception were iden-
tiﬁed in the left lateral side of a previous cesarean section scar
(Fig. 4A, arrow). Gestational products were ﬁrmly attached to the
ﬁbrous tissue of the previous cesarean section scar, although hys-
teroscopic resection with a monopolar loop electrode was suc-
cessfully completed without signiﬁcant hemorrhagic complications
(Fig. 4B). An immunohistochemical study showed positive staining
for b-hCG in the degenerated trophoblastic cells (Fig. 4C). Fifty-
seven days after the initial MTX administration, the serum b-hCG
reached a normal level. Menstruation resumed 82 days after the
initial treatment, and the disease course was uneventful.examination. (A) Transvaginal color Doppler ultrasonography shows the gestational sac
vious cesarean scar. (B) The sagittal T2-weighted magnetic resonance image shows the
ar. (C) The coronal reconstructed multiplanar image of three-dimensional computed
shunt-like structure supplied from the left uterine artery (arrow) with a thick draining
Fig. 3. Changes in the diagnostic ﬁndings of the cesarean scar pregnancy after methotrexate (MTX) administration. (A) The transvaginal color Doppler ultrasonography image shows
persistent peritrophoblastic blood ﬂow (arrow) after the initial cycle of MTX administration when moderate hemorrhage occurred. The fetal pole is present at this time, although
fetal cardiac activity could not be detected (arrowhead). (B) The transvaginal color Doppler ultrasonography image shows an increase in the size of the gestational sac (arrow) and
persistent peritrophoblastic blood ﬂow, despite a decrease in the serum beta-human chorionic gonadotropin value after three cycles of systemic MTX administration. (C) After three
cycles of MTX administration, the coronal three-dimensional computed tomographic angiographic image fused with the multiplanar reconstruction image shows marked reduction
of the neovascularized mass at the placental site (arrow) with the disappearance of the draining vein (arrowhead).
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Ranking among the rarest forms of ectopic gestation, CSP is a
potentially life-threatening condition [1,2]. Because accumulated
data indicate that expectant management of CSP is rarely successful
and leads to a catastrophic outcome, immediate termination of theFig. 4. Hysteroscopic resection of the gestational products at the previous cesarean scar wa
conception are identiﬁed by the arrow on the left lateral side of the previous cesarean sca
successfully resected by hysteroscopic surgery without signiﬁcant hemorrhagic complicatio
Immunohistochemical staining shows positive localization of beta-human chorionic gonadpregnancy is required for uterine preservation once the diagnosis is
made, as in the present patient.
In addition to the clinical symptoms, assessing uteroplacental
neovascularization around CSP by using color Doppler ultrasono-
graphic imaging could be important when determining which
treatment would be justiﬁed [5]. Our previous reports furthermores performed 44 days after the initial methotrexate administration. (A) The products of
r. The retained gestational products ﬁrmly attached to the ﬁbrous cesarean scar were
ns. (B) The macroscopic ﬁndings of hysteroscopically resected gestational products. (C)
otropin in the degenerated trophoblastic cells (the scale bar ¼ 200 mm).
A. Takeda et al. / Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 385e388388indicated that recently evolving 3D-CTA technologydbecause of its
accuracy and rapidity in localizing a vascular mass with its feeding
arterydis a feasible minimally invasive diagnostic modality for
assessing uteroplacental neovascularization that develops in cases
of CSP with signiﬁcant hemorrhage [3].
Because the CSP was diagnosed at an early stage without
hemorrhage in the present patient, medical management by
systemic MTX administration was initially chosen. Similar to the
results shown in previous case series [6], a temporary rise in the
b-hCG value occurred after the initial cycle of MTX administration.
The b-hCG value subsequently decreased, although the gestational
sac with peritrophoblastic blood ﬂow continued to enlarge.
Furthermore, it became evident that it is difﬁcult to achieve com-
plete resolution of gestational products by using medical MTX
therapy alone because of liver damage that was most likely caused
by MTX.
When the need emerged to determine how to intervene to
remove the retained gestational products, the interval change of
uteroplacental neovascularization was evaluated by 3D-CTA. The
prominent vascular mass, which had an arteriovenous shunt-like
structure in the left lateral lower uterine segment prior to MTX
therapy, apparently regressed after three cycles of MTX injections.
Persistent peritrophoblastic blood ﬂow was still detected by color
Doppler ultrasonography, although ﬁndings obtained by 3D-CTA
showed marked reduction of blood ﬂow around the retained
placenta at the cesarean scar. On the basis of this ﬁnding, the ﬁrmlyattached placental tissue was successfully removed by hystero-
scopic resection without preventive uterine arterial embolization.
In conclusion, the present case report emphasizes that 3D-CTA
could be a useful diagnostic modality to evaluate the degree and
localization of uteroplacental neovascularization in CSP prior to
individually selecting the therapeutic approach to preserve fertility.
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